Lexicon Pharmaceuticals: Q3 Earnings Insights

Shares of Lexicon Pharmaceuticals LXRX rose 5.7% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 330.00% year over year to ($0.43), which missed the estimate of $0.26.

Revenue of $6,634,000 decreased by 97.75% from the same period last year, which missed the estimate of $16,870,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Recent Stock Performance

52-week high: $5.33

52-week low: $1.22

Price action over last quarter: down 33.51%

Company Description

Lexicon Pharmaceuticals Inc is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates. Its drugs candidates include XERMELO (telotristat ethyl), an orally-delivered small molecule drug, in the United States for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog, or SSA, therapy in adults inadequately controlled by SSA therapy; Zynquista (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 diabetes; sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease; and LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.